Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label safety, pharmacokinetics, and efficacy trial of sebetralstat in pediatric hereditary angioedema
jRCT2031240670Completed
- Sponsor
- KalVista Pharmaceuticals
- Start
- Apr 2025
- Modality
- Small Molecules
01
Overview
Open-label, single-arm trial of sebetralstat in hereditary angioedema (HAE), sponsored by KalVista Pharmaceuticals. Primary endpoint: Safety and tolerability of sebetralstat. Started Apr 2025; status: completed.
02
Drugs
sebetralstat
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on jRCT2031240670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240670.